Search the Newsreel

REPL DEADLINE: Levi & Korsinsky Reminds Replimune Group, Inc. Investors of Upcoming Securities Class Action Deadline

Levi & Korsinsky, LLP is reminding investors of Replimune Group, Inc. (NASDAQ: REPL) about an upcoming securities class action deadline. The lawsuit is filed on behalf of shareholders who purchased securities between October 20, 2025, and April 10, 2026, following a significant 84% stock …

SurgePays Inc Revenue Breakdown – HAM:9B90

SurgePays Inc. (HAM:9B90) generated €48.50 million in revenue last year, with the majority (€37.05 million) coming from its Point-of-Sale and Prepaid Services segment. The United States was the primary geographic contributor, accounting for all of the company's revenue.

YXT.COM Group Holding Limited Sponsored ADR (YXT) Live Share Price, Invest From India

This article provides a detailed financial overview of YXT.COM Group Holding Limited Sponsored ADR (YXT), including its live share price, historical performance, fundamental indicators, and valuation trends. It also offers insights for Indian investors on how to invest in YXT shares through the INDmoney …

Why SK Hynix Stock Popped Today

Korean memory chip manufacturer SK Hynix (NASDAQ: SKHY) stock jumped 4% through 10 a.m. ET Monday -- and it has Donald Trump to thank for it. Over the weekend, Trump Commerce Secretary Howard Lutnick told The Wall Street Journal that the Trump administration "is …

Reasons Why You Should Retain RSG Stock in Your Portfolio Now

Republic Services, Inc. RSG is gaining from continued demand for its essential waste services across North America. The company's disciplined pricing strategies and robust Collection segment growth fuel its long-term prospects. Increased sustainable investments in artificial intelligence (AI) and shareholder-friendly policies increase the stock's …

Dharan Infra-EPC seeks 7-day extension for SEBI data submission

Home Depot-Aktie bleibt unter dem Widerstand bei 337,57 $ stehen, da gemischte Momentum-Signale anhalten: Wochenanalyse

Cantor Fitzgerald Downgrades Eyepoint Pharmaceuticals (NASDAQ:EYPT) to Neutral

Cantor Fitzgerald downgraded Eyepoint Pharmaceuticals (NASDAQ:EYPT) from an "overweight" to a "neutral" rating, causing shares to fall by $10.59 to $4.16, near its 52-week low. Despite the downgrade, the consensus among analysts remains a "Moderate Buy" with a target price of $44.38. The company …

Super Hi to Report Second Quarter 2026 Financial Results on Wednesday, August 26, 2026

Super Hi International Holding Ltd. (NASDAQ: HDL and HKEX: 9658) announced it will report its unaudited financial results for the second quarter of FY2026 on Wednesday, August 26, 2026, before the U.S. markets open. The company's management will host an earnings conference call at …

Walmart (NYSE:WMT), Target (NYSE:TGT) and Home Depot (NYSE:HD) Earnings This Week: Is the US Consumer Finally Weakening?

Pony AI earnings ahead: Robotaxi expansion meets widening losses

Pony AI is set to report Q2 earnings with analysts expecting widening losses due to heavy investment in scaling its robotaxi and autonomous freight businesses, despite significant global expansion efforts. The company's stock is trading well below its 52-week high, but analysts remain bullish, …

Repco Home Finance Q1FY27 profit rises 6% as NII grows 10%

Will Home Depot (HD) Stock Rise or Fall After Q2 Earnings?

Home Depot Stock (HD) Could Move 4.3% on Q2 Earnings, Options Market Signals

CORT Looks 65.7% Overvalued on GF Value™

Corcept Therapeutics (CORT) has seen a significant stock gain of 228.94% year-to-date but is deemed 65.7% overvalued by GuruFocus' GF Value™ metric, trading at $114.47 against an intrinsic value of $69.10. Despite a strong GF Score™ of 85/100, reflecting robust growth and profitability, the …

B.C.'s Only Permitted Mill Signs a New Precious-Metals Partner

Nicola Mining Inc. has signed a Mining and Milling Profit Share Agreement with Red Eye Resources Ltd., a privately held precious metals explorer based in British Columbia. Under this agreement, Red Eye Resources can transport qualifying precious-metal material to Nicola's Merritt Mill for processing, …

Nicola Mining Enters into Mining and Milling Profit Share Agreement with Red Eye Resources

Nicola Mining Inc. announced a Mining and Milling Profit Share Agreement with Red Eye Resources Ltd., a privately held mineral exploration company. Under the agreement, Red Eye Resources will transport qualifying precious-metal mineralized material to Nicola's Merritt Mill for processing, with profits shared equally. …

Nicola Mining: Exclusive mill licence brings new profit-sharing arrangement

Nicola Mining has expanded its market position by entering a profit-sharing agreement with Red Eye Resources. This partnership will utilize Nicola's fully permitted Merritt Mill in British Columbia, the only facility authorized to process third-party gold and silver ore in the region. The collaboration …

Nicola Mining partners with Red Eye Resources to share profits from precious metal milling in BC.

Nicola Mining Inc. has entered a profit-sharing agreement with Red Eye Resources, allowing Red Eye to process mineralized material at Nicola's Merritt Mill in British Columbia. The partnership focuses on precious metals, with profits split equally, and aims to support smaller mining projects without …

EYPT Stock Slips As Insider Plans Share Sale

EyePoint Pharmaceuticals (EYPT) stock has dropped significantly following news of an insider's plan to sell securities, as indicated by an amended Form 144/A filing. While the company has a strong balance sheet with substantial cash reserves and a recent multi-week price climb, the insider …

Form 8K Eyepoint Pharmaceuticals Inc For: 17 August By Investing.com

This article reports on the filing of a Form 8K by Eyepoint Pharmaceuticals Inc. on August 17th. The brief piece includes the stock symbol EYPT, which is noted to be down 68.88%. No further details about the content of the Form 8K are provided.

Eyepoint Pharmaceuticals stock hits 52-week low at $4.06 By Investing.com

Eyepoint Pharmaceuticals Inc. (EYPT) stock recently hit a 52-week low of $4.06, despite a 33% increase over the past year. Analysts maintain a bullish outlook with an average price target suggesting a 58% upside. The company recently announced stockholder approval for an increase in …

EYPT Maintains Buy Rating by Chardan Capital -- Price Target Set at $65

Chardan Capital maintained its Buy rating for EyePoint Pharmaceuticals (EYPT) with a price target of $65.00, despite the stock being significantly overvalued according to GuruFocus's GF Value™ of $0.36 versus its current price of $14.76. The company also received a low GF Score™ of …

Home Depot (HD) Stock Looks Fairly Valued After CEO Medical Leave

Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Home Depot stock has delivered a 17.1% gain over the past five years, and current checks suggest it now trades close to what a …

How Olipop hit $500M in revenue and beat Pepsi's Poppi: Fmr CEO

Olipop Co-Founder and former CEO Ben Goodwin breaks down to Yahoo Finance Executive EditorBrian Sozzi the brand's massive $500 million growth, how they reclaimed the top spot from Poppi, and why health-conscious consumers ultimately don't trust Big Soda giants like Coke and Pepsi. Ben …

Eyepoint Pharmaceuticals (NASDAQ:EYPT) Given "Buy" Rating at Chardan Capital

SK Hynix Shares Gain 3.9% with U.S. ADRs Trading at 48% Premium

Stifel Nicolaus Increases Home Depot (NYSE:HD) Price Target to $340.00

Radiopharm Theranostics To Meet with U.S. FDA to Align on Pivotal Phase 3 Trial Design for RAD 101 in Diagnosis of Brain Metastases

Radiopharm Theranostics announced an End-of-Phase 2 meeting with the U.S. FDA on October 1, 2026, to align on the design of a pivotal Phase 3 trial for RAD101. This imaging agent diagnoses recurrent brain metastases and showed 93% concordance with MRI in its Phase …

Radiopharm schedules FDA meeting for brain imaging agent RAD101 By Investing.com

Radiopharm Theranostics has scheduled an End-of-Phase 2 meeting with the FDA for October 1, 2026, to discuss the Phase 3 trial design for its brain imaging agent, RAD101. RAD101, which has FDA Fast Track Designation, is developed to distinguish recurrent brain metastases from treatment …

EYPT Looks 4000.0% Overvalued on GF Value™

EyePoint Pharmaceuticals (EYPT) is considered 4000.0% overvalued based on GuruFocus's GF Value™ metric, trading at $14.76 against an estimated fair value of $0.36. This extreme valuation comes despite its Duravyu wet AMD trial showing mixed results—failing the primary endpoint in the overall dataset but …

PROCEPT BioRobotics® to Attend the Baird 2026 Global Healthcare Conference on September 15, 2026

PROCEPT BioRobotics SAN JOSE, Calif., Aug. 17, 2026 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics Corporation (the "Company") (Nasdaq: PRCT), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced members of management will present and host investor meetings …

PROCEPT sets a Sept. 15 New York date with healthcare investors

PROCEPT BioRobotics (Nasdaq: PRCT) announced that its management team will participate in the Baird 2026 Global Healthcare Conference in New York City on September 15, 2026. They will present and host investor meetings at the conference. Following this announcement, the company's stock, PRCT, experienced …

A PET scan matched MRI in 93% of lesions—what comes next?

Radiopharm Theranostics has scheduled an End-of-Phase 2 meeting with the U.S. FDA for October 1, 2026, to discuss the pivotal Phase 3 trial design for RAD101, an imaging agent for recurrent brain metastases. The company's Phase 2b trial showed a 93% concordance between MRI …

Weekly Recap: JDE Peet's deal and Aaron Alt named independent director

Keurig Dr Pepper (KDP) exceeded Q2 estimates with $7.31 billion in sales and $210 million net income, partly due to the JDE Peet's deal. The company also announced the appointment of Aaron Alt as an independent director and launched new co-branded Dr Pepper shakes …

Unpacking Q2 Earnings: Repligen (NASDAQ:RGEN) In The Context Of Other Drug Development Inputs & Services Stocks

Unpacking Q2 Earnings: Repligen (NASDAQ:RGEN) In The Context Of Other Drug Development Inputs & Services Stocks Quarterly earnings results are a good time to check in on a company's progress, especially compared to its peers in the same sector. Today we are looking at …